Log in to search using one of your social media accounts:


Tolerability, persistence and satisfaction. Retrospective cohort study in patients with overactive bladder syndrome treated with transdermal Oxybutynin under Standard ClinicAl pRactice. OSCAR Study.

CONCLUSIONS: The study performed in patients with OAB shows that OXY-TDS provides low incidence of systemic adverse effects, including dry mouth, high persistence, improved adherence rates and high satisfaction of patients after one year of treatment. PMID: 28678009 [PubMed - in process]
Source: Archivos Espanoles de Urologia - Category: Urology & Nephrology Tags: Arch Esp Urol Source Type: research

Related Links:

Condition:   Overactive Bladder Syndrome Interventions:   Drug: herbal patch;   Drug: placebo patch Sponsor:   En Chu Kong Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSION: All three treatments lead to effective short-term reduction of urgency in women with OAB, but longterm efficacy evaluation is required. PMID: 29781068 [PubMed - as supplied by publisher]
Source: Urology Journal - Category: Urology & Nephrology Authors: Tags: Urol J Source Type: research
Having an overactive bladder can be a very challenging condition, but there are many ways in which people can improve their symptoms. These include monitoring the foods and drinks that they consume, as well as avoiding alcohol, caffeine, and spicy foods. Learn more about the overactive bladder diet here.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Overactive Bladder (OAB) Source Type: news
The Neuromodulation market is rapidly growing and has become host to many medtech companies. StimGuard is the latest firm to make significant moves in the space, as it has received CE mark for a wireless neuromodulation device to treat chronic symptoms of overactive bladder. The Pompano Beach, Fla.-based company said its StimGuard would be available in Europe in the summer of 2018. “A wireless system that enables urologists to inject such a clinically proven therapy represents a shift in the field where there has only been one option for over 15 years,” Karl-Dietrich Sievert MD, PhD, professor and co-chairman o...
Source: MDDI - Category: Medical Devices Authors: Tags: Implants Source Type: news
StimGuard said today it won CE Mark approval in the European Union for its sacral nerve stimulator designed to treat intractable symptoms of overactive bladder, with plans to launch the device in the EU this summer. The Pompany Beach, Fla.-based company touted that the StimGuard SNS system can be implanted through a needle without a surgery, as the device is 95% smaller than other similar sacral nerve stimulation devices on the market. The system uses an Apple iPad as a programming console, the company added. “A wireless system that enables urologists to inject such a clinically proven therapy represents a shift...
Source: Mass Device - Category: Medical Devices Authors: Tags: Neuromodulation/Neurostimulation Regulatory/Compliance StimGuard Source Type: news
Pharmacotherapy of overactive bladder (OAB) typically involves treatment with an antimuscarinic or mirabegron, a β3-adrenoceptor agonist, but real-world evidence on their use, including treatment access, persistence, and switching, is limited. Here, we describe the design of a prospective, multicenter, non-interventional registry of patients beginning a new course of OAB pharmacological therapy in routine cli nical practice.
Source: Contemporary Clinical Trials - Category: Radiology Authors: Source Type: research
BJU International, EarlyView.
Source: BJU International - Category: Urology & Nephrology Authors: Source Type: research
Molecules, Vol. 23, Pages 1191: Structure-Activity Relationships Based on 3D-QSAR CoMFA/CoMSIA and Design of Aryloxypropanol-Amine Agonists with Selectivity for the Human β3-Adrenergic Receptor and Anti-Obesity and Anti-Diabetic Profiles Molecules doi: 10.3390/molecules23051191 Authors: Marcos Lorca Cesar Morales-Verdejo David Vásquez-Velásquez Juan Andrades-Lagos Javier Campanini-Salinas Jorge Soto-Delgado Gonzalo Recabarren-Gajardo Jaime Mella The wide tissue distribution of the adrenergic β3 receptor makes it a potential target for the treatment of multiple pathologies s...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
International Journal of Urology, EarlyView.
Source: International Journal of Urology - Category: Urology & Nephrology Authors: Source Type: research
URO-1, based in Winston-Salem, North Carolina, got FDA approval for its Repris Bladder Injection System. The product is designed for delivering Botox injections into the bladder as a treatment option for overactive bladder. The device, which is suppo...
Source: Medgadget - Category: Medical Devices Authors: Tags: Urology Source Type: blogs
More News: Men | Overactive Bladder | Overactive Bladder Syndrome | Oxybutynin | Study | Urology & Nephrology | Women